Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Black on Biomarkers for Immunotherapy in Bladder Cancer

August 10th 2017

Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses biomarker development in bladder cancer.

Dr. Kaouk on Challenges Facing Surgery for RCC

August 10th 2017

Jihad Kaouk, MD, urologist, Cleveland Clinic, discusses challenges regarding robotic surgery for patients with renal cell carcinoma (RCC).

Dr. Feldman on Managing Patients With Prostate Cancer Under Active Surveillance

August 9th 2017

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses managing patients with prostate cancer under active surveillance.

Dr. Lallas on Ongoing Trials Investigating Immunotherapy for GU Cancer

August 8th 2017

Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses ongoing trials investigating immunotherapy regimens for patients with genitourinary malignancies.

Dr. Chowdhury on Sequencing of Immunotherapy Regimens for RCC

August 8th 2017

Simon Chowdhury, PhD, MA, MBBS, MRCP, consultant medical oncologist specializing in urological cancer, Sarah Cannon Research Institute, United Kingdom, discusses sequencing of immunotherapy regimens for patients with renal cell carcinoma (RCC).

Dr. Black Discusses Immunotherapy Biomarkers in Bladder Cancer

August 8th 2017

Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses immunotherapy biomarkers in bladder cancer.

Dr. Gupta Discusses Adjuvant Immunotherapy in Kidney Cancer

August 8th 2017

Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses adjuvant immunotherapy in kidney cancer.

Dr. Choueiri on Trials Investigating Combination Regimens for RCC

August 7th 2017

Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses trials investigating combinations for patients with renal cell carcinoma (RCC).

Genomic Landscape of Prostate Cancer Aligns With Breast Cancer Subtypes

August 4th 2017

A comparison of the genomic risk profiles of patients with low-risk prostate cancer who are candidates for active surveillance against higher-risk patients, discovered that substantial genomic heterogeneity exists among patients with prostate cancer.

Choueiri Discusses Avelumab/Axitinib, Other Novel RCC Combos

August 4th 2017

Toni Choueiri, MD, reflects on avelumab/axitinib results and other emerging combos in RCC.

Dr. Rini on the Efficacy of Axitinib and Pembrolizumab in RCC

August 4th 2017

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the efficacy of pembrolizumab (Keytruda) and axitinib (Inlyta) combined in patients with renal cell carcinoma (RCC).

Dr. Rosenberg on Immunotherapy in Non-Metastatic Muscle Invasive Bladder Cancer

August 3rd 2017

Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses immunotherapy in patients with non-metastatic muscle invasive bladder cancer.

Dr. Choyke on Which Patients Benefit From Active Surveillance in Prostate Cancer

August 3rd 2017

Peter Choyke, MD, FACR, chief of Molecular Imaging Program, National Cancer Institute, discusses which patients with prostate cancer benefit from active surveillance.

Experts Explain Impact of LATITUDE Abiraterone Data in Prostate Cancer

August 3rd 2017

Jorge Garcia, MD, and Kim Chi, MD, share their insights on the LATITUDE trial in prostate cancer.

Dr. Lara on the Role of Sunitinib for Renal Cell Carcinoma

August 3rd 2017

Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses the role of sunitinib (Sutent) for patients with renal cell carcinoma (RCC).

Dr. Atkins on Sequencing of Immunotherapy Combination Regimens

August 3rd 2017

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses sequencing of immunotherapy combination regimens for patients with renal cell carcinoma (RCC).

Pembrolizumab Plus Epacadostat Active in RCC

August 2nd 2017

Primo N. Lara Jr, MD, discusses the KEYNOTE-037 pembrolizumab/epacadostat findings in patients with advanced RCC, and how the combination could change treatment in this population.

Dr. Balar on PD-L1 Testing for Urothelial Cancer

August 2nd 2017

Arjun V. Balar, MD, assistant professor of medicine, Division of Hematology and Oncology, Perlmutter Cancer Center, NYU Langone Medical Center, discusses PD-L1 testing and the development of biomarkers for PD-L1 antibodies for patients with urothelial carcinoma.

Dr. Lara on the Potential Role of IDO Inhibitors in the Treatment of RCC

August 1st 2017

Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses the potential role of IDO inhibitors in the treatment of patients with renal cell carcinoma.

Dr. Garcia Discusses the LATITUDE Study in Prostate Cancer

July 31st 2017

Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses the LATITUDE study in prostate cancer.